Vicore Pharma Holding AB

Vicore Pharma Holding AB
About Us
Change country

Follow us:
Share:
Subscribe:

About Us

Vicore is a rare disease pharmaceutical company focused on rare lung disorders and related indications. The company currently has three drug development programs, VP01, VP02 and VP03.VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (“IPF”), pulmonary fibrosis in systemic sclerosis (“SSc”) and COVID-19. VP02 is based on a new formulation and delivery route of an existing immunomodulatory compound (an “IMiD”). VP02 focuses on the underlying disease and the severe cough associated with IPF. VP01 and VP02 are also being actively evaluated for other indications within the field of interstitial lung diseases which have a significant unmet need. VP03 includes follow-up molecules to VP01. The company's shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Vicore Pharma publishes prospectus in connection with its listing on Nasdaq Stockholm

Mon, Sep 16, 2019 17:30 CET

Gothenburg,September 16, 2019- On September 11, 2019, Vicore Pharma Holding AB (publ) (”Vicore” or the “Company”) announced that Nasdaq Stockholm’s listing committee had approved that the Company’s shares are admitted to trading on Nasdaq Stockholm’s main market. Today, on September 16, 2019, the prospectus that has been prepared in connection with the listing was approved and registered by the Swedish Financial Supervisory Authority and is now available on Vicore’s website, www.vicorepharma.com.The first day of trading on Nasdaq Stockholm’s main market is September 27, 2019. The last day

There are no items matching the current filter

There are no more items matching the current filter

Back to top

Share

About Us

Vicore Pharma publishes prospectus in connection with its listing on Nasdaq Stockholm

Media